At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 28 enrolled
Drug / intervention
Pitavastatin (NK-104) +1 moredrug
Likely dose
Pitavastatin (NK-104) 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Drug-Drug Interaction Study to Assess the Effects of Steady-State Darunavir/Ritonavir on Steady-State Pitavastatin in Healthy Adult Volunteers
In Brief
A Phase 4 clinical trial evaluating Pitavastatin (NK-104) and Darunavir/Ritonavir (Prezista) for Healthy. Completed, enrolled 28 participants across 1 site.
Detailed Summary
This is a Phase 4, single center, open label, fixed-sequence, multiple dose, 2-way drug-drug interaction study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
Primary CompletionJun 2011
First PostedAug 2011
TodayJul 2026
First PostedAug 24, 2011
Enrollment StartApr 1, 2011
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.9 years ago
Interventions
Pitavastatin (NK-104)drug
Pitavastatin (NK-104) 4mg once daily (QD)
Darunavir/Ritonavir (Prezista)drug
Darunavir/Ritonavir (Prezista) 800 mg/100 mg